Dr. Harsh Vardhan explained how COVISHIELD approval is different from COVAXIN

Advertisements
Advertisements

Dr. Harsh Vardhan tweeted that COVAXIN has been approved for use in ‘Clinical Trial Mode’ in case of emergency.

The country’s health minister, Dr Harsh Vardhan, tweeted about how the vaccine was approved by the Serum Institute of India’s Covishield in case of an emergency. Let me inform you that on Sunday, the Drug Controller General of India (DCGI) approved the limited emergency use of the Covid-19 vaccine ‘Kovishield’ and the indigenously developed vaccine ‘Kovacin’ of India Biotech produced by the Serum Institute of India. Manzoor, who has paved the way for a massive vaccination campaign, told a news conference on Sunday.

India’s Drug Controller General V.G. Somani said the two companies had submitted trial run statistics and both had been approved for “limited use”.

Dr. Harsh Vardhan tweeted that COVAXIN has been approved for use in ‘Clinical Trial Mode’ in case of emergency, under which COVAXIN will be tracked and monitored as the test takers are vaccinated.

NDTV India’s Morning News reported that Kovaxin has been approved in clinical trial mode, which also means that people who have had a corona infection before will not be vaccinated because they will be included in the trial. Vaccines are given that have not been infected before.

Newsbip

fwn({ app_id: 'vbfSDYYeMhsSGS7hb7LjvAStfDroYVRC', placement: 'middle', page_type: 'article', target: document.getElementById('fwn_videos') }); });

Listen to the latest songs, only at JioSaavn.com

Advertisements
Dr. Harsh Vardhan explained how COVISHIELD approval is different from COVAXIN
Dr. Harsh Vardhan explained how COVISHIELD approval is different from COVAXIN

We will be happy to hear your thoughts

Leave a Reply

NewsTree News - Latest News For You.
Logo